Inorganic arsenic: a need and an opportunity to improve risk assessment. by Chappell, W R et al.
Reseamch
Revievvs
Inorganic Arsenic: A Need and an Opportunity to Improve Risk Assessment
W.R. Chappell,I B.D. Beck,2K.G. Brown,3 R. Chaney,4 C. Richard Cothern,5 K.J. Irgolic,6D.W North,78 L Thornton,9
and T.A. Tsongas'0
1University of Colorado at Denver, Denver, CO 80217 USA; 2Gradient Corporation, Cambridge, MA 02138 USA; 3Kenneth G. Brown Inc.,
Chapel Hill, NC 27516 USA; 4U.S. Department of Agriculture, Beltsville, MD 20705 USA; 5U.S. Environmental Protection Agency,
Washington, DC 20460 USA; 6lnstitute for Analytical Chemistry, University of Graz, Graz, Austria; 7Decision Focus Inc., Mountain View,
CA 94041 USA; 8Stanford University, Stanford, CA 94305 USA; 91mperial College of Science, Technology and Medicine, London,
England; 10Washington State University, Pullman, WA 99164 USA
This paper presents views on the current status of(inorganic) arsenic risk assessment in the
UnitedStatesandr research needed to setstadards fordrinkingwater. Theopinions
are thoseoftheArsenic Task Force ofthe Society forEnvironmental Geohemistry and Health,
which has met i since 1991 to stu isse relatd to arsenic risk aessment and has
heldworikhops and in nial o rnces on arsenic The topic ofthispaper is made time
by cunt sdctific in in exure to and aders health effec ofarsenic in the United
States andpasage ofthe Safe Drinin WaerAct Amendments of1996, which has provisions
forareseaschprogram onarsenicandaschedulemandatigtheEPAtorevisethemaximum con-
taminant levelofarsecindrinkingwaterbytheyear2001. Ourcentralpremise andrecommen-
da6tions are nbthe risk ofadves health effcts associated with arsenic in drinking
water is unknown for low arsenic oncenions found in the United States, such as at the cur-
rent interim a i on amintkvelof50pg/l andbelow.Arenic-related research shouldbe
directd atanswerng t question. Newepidemiological studies are needed to provide data for
reliable dose-response aesmenuts ofarsenic and for skin cancer, bladder cancer, or other end-
points to beusd bytheEPAfor glation. Furthertoxicologicalrsarch, alongwidt the obser-
vationa datafiom epidemiol is need to ine ifthedose-rwponse reationship at low
leel is more con t withshe current assumpton oflow-dose linearity or the existence of a
prical t d Other Vreommendations indude addingfoodborne arsenic to the alculation
oftot arsenic inta, caltion oftotal aec ine, and eou ng cooperaive c
within the United States and between the United States and affected countries. Key werdr
arsenic, ancer,dose re, d wrining wate,fod,riskassessment.
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In selected regions of the world, long-term
ingestion ofarsenic at relatively high concen-
trations in drinking water has been associat-
ed with disorders of the skin ranging from
hyperpigmentation or hypopigmentation
and hyperkeratosis to various skin cancers;
with cancers ofthe bladder, liver, lung, kid-
ney, colon, and other internal organs; with
peripheral vascular disorder that may include
blackfoot disease; and with other confirmed
or suspected adverse effects including dia-
betes, ischemic heart disease, reproductive
effects, and impairment of liver function
(1-17). Observed toxicity has largely been
associated with inorganic arsenic, which is
the focus ofthis paper. These adverse health
effects have been observed in locations where
arsenic leaches into well water or thermal
springs from the substratum or percolates
into surface water from soitl rich in volcanic
sediment, as may be found in Bangladesh,
West Bengal India, Thailand, Taiwan,
China, Inner Mongolia, Mexico, Argentina,
Chile, Finland, and Hungary (18-27).
Remediation has reduced arsenic concentra-
tions in water used forduinking or irrigation
in some locations but not in others. In India
and Bangladesh, for example, hundreds of
thousands of persons are currendy exposed
to highly toxic levels of arsenic in water
from tube wells used fior drinking and irri-
gation (18-21).
In the United States, total nonoccupa-
tional exposure to irnorganic arsenic (here-
after called arsenic) from all routes is pri-
marily by ingesticin of water and food
(28-34). Exposure in the United States
from fossil fuel combustion is now relative-
ly low (35,36). Air emissions of arsenic
from mineral processing and smelting have
decreased during the past two decades due
to the increased effectiveness of air pollu-
tion controls and metal refining processes.
Ingestion ofarsenic in soil remains a poten-
tial but limited route ofexposure for young
children in most situations. Typical daily
intake from food for a U.S. adult is on the
order of 10-30 pig/day (30,34). The drink-
ingwater ofabout 98% ofthe U.S. popula-
tion is below 10 pg/l (28), well below the
current interim maximum contaminant
level (MCL) of 50 pg/l, but some portion
ofthe remaining 2% ofthe population use
drinking water with arsenic concentrations
that may reach 50-100 pg/l (31). The EPA
(1) assumes for its risk calculations (where
risk is the increased chance that an individ-
ual will develop skin cancer from lifetime
daily arsenic intake of a specified amount)
that a U.S. adult consumes 2 liters
water/day. Thus, total intake of arsenic
from food and water is a few tens ofmicro-
grams per day for most people in the
United States, but much higher for some
people in areas with high arsenic concentra-
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tions in drinking water. Ifthere is a health
risk at intake of a few tens of micrograms
per day, then nearly everyone in the U.S.
population is at some risk from exposure to
arsenic. The size ofthe U.S. population at
risk and the magnitude ofthe risk depend
critically on the toxicity oflong-term expo-
sure to small doses ofarsenic.
The areas ofrelatively high arsenic con-
centrations in drinking water in the United
States aremostlycommunities in thewestem
and southwestem states andAlaska, typically
served by one or more small water systems.
One of the largest U.S. communities with
elevated arsenic in drinking water is
Hanford, California. Epidemiological studies
ofhealtheffects inhigh-arsenicregionsofthe
United States have not shown an impact of
arsenic, but sample sizes tended to be small
(37,38). The World Health Organization
has adopted a provisional guideline for
drinking water of 10 pg/l (3, and Canada
has lowered its guideline to 25 pg/l, consid-
ered an interim value with intent to lower
further (33). Both guidelines were based on
risk calculations for skin cancer from the
Taiwan study used in the 1988 EPA risk
assessment (1). A reduction ofthe MCL in
the United States to 10 pg/l would not have
much impact on human exposure for most
ofthe U.S. population, but it could signifi-
cantly reduce the exposure in selected small
populations. Reductions below 10 pg/l
would increasingly affect a larger portion of
theU.S. population.
The potential to determine the nature
and magnitude ofhealth risks at low daily
intakes typical ofthe United States is limited
by the lack of a good animal model for
experimentation, inadequate dose-response
data on humans, and incomplete knowledge
ofthe uptake, biotransformation, and distri-
bution of arsenic in the body. Drinking
water in locations where arsenicism (arsenic-
induced skin disorders) and more severe dis-
orders have been observed are relativelyhigh.
There is no direct observational evidence
that demonstrates severe disorders at less
thanseveralhundred micrograms perliter.
At the low end of the exposure scale,
arsenic toxicity may not persist down to
zero concentrations. For example, the cur-
rent EPA risk assessment of arsenic (1)
notes that "experimental studies with rats,
chicks, minipigs, and goats demonstrate the
plausibility that arsenic, at least in inorganic
form, is an essential nutrient," but adds that
nutritional essentiality for humans has not
been established [also see Uthus (39,40)].
Aside from whether trace amounts of
arsenic may be beneficial, some mechanistic
studies on metabolism, genotoxicity, and
other factors suggest the dose-response rela-
tionship may be nonlinear, i.e., there may
either be a threshold (dose level below
which there is no effect) or the dose is rela-
tively less effective at low levels. As will be
discussed, however, consensus is lacking on
the nonlinearity issue, and even ifthe con-
cept is correct, there is a limited basis for
incorporating it into dose-response assess-
ment at the individual or population level.
Thus, the magnitude ofthe risk ofadverse
health effects at the current MCL for drink-
ing water in the United States is unknown.
The current information is inadequate as a
basis fordeterminingtheMCL.
Responsibility for setting the MCL for
arsenic in drinking water lies with the EPA
under the Safe Drinking Water Act
(SDWA). The EPA risk assessment for
arsenic is also used as the basis forevaluating
the need for remedial actions for soil at haz-
ardous waste sites listed under Superfund
(41). The current MCLof50p/I wasset in
the National Interim Primary Drinking
WaterRegulation of1976 to protect against
chronic toxicity rather than cancer. An EPA
risk assessment based on the lifetime risk of
skin cancer appeared as a special report of
EPA's RiskAssessment Forum in 1988 [(1);
see also Brown et al. (424], but the MCL
was not subsequently revised. In 1996,
Congress passed the Safe Drinking Water
ActAmendments (43) with a provision that
requires the EPA to propose a regulation for
arsenic in drinking water not later than 1
January 2000 and to issue a final regulation
ayearlater.
Thus, it is timely to consider regulatory
methods of cancer risk assessment and
research needs in relation to arsenic. The
EPA, theAmericanWaterWorksAssociation
Research Foundation (AWWARF), and the
Association of California Water Agencies
have recently pooled resources totaling $3
million to fund additional arsenic-related
research. Following the schedule mandated
by the 1996 Safe Drinking Water Act
Amendments (43), the EPA has drafted a
lengthy research plan for arsenic. This paper
describes issues central to risk assessment of
arsenic, induding an overview ofregulatory
procedures and default assumptions used for
riskassessment, and makes recommendations
to improve risk assessment of arsenic. A
description ofwho we are, and the reasoning
behind our recommendations, is set forth in
thesectionsthatfollow.
The SEGH Arsenic Task Force
The SEGH Arsenic Task Force is a group
of scientists assembled under the auspices
of the Society for Environmental
Geochemistry and Health (SEGH), an
international professional societyspecializing
in methods for assessing exposure to trace
elements in the environment and the health
and environmentl impacts from such expo-
sure. Asimilar SEGH task force on lead has
produced a book (44) and a review artide
(45). This commentary reflects our views as
individual scientists and not theviews ofthe
academic, industry, government, or consult-
ing/contract research organizations with
which we areassociated.
We view arsenic as an example ofa sub-
stance for which better scientific informa-
tion is needed to improve risk assessment
needed for regulatory decisions. The SEGH
held a special session on arsenic at its annu-
al meeting in 1991 (46) and subsequently
organized international conferences on
arsenic in 1993 (3) and 1995 (4). Between
these meetings, SEGH held a specialized
Workshop on Arsenic Epidemiology and
Pharmacokinetic Modeling in Annapolis,
Maryland, in 1994.
How U.S. Regulatory Agencies
Estimate Cancer Risk
U.S. regulatory agencies presently conduct
cancer risk assessments using the default
assumption that carcinogens do not have a
threshold (47) and that excess risk is pro-
portional to dose at low values (commonly
referred to as low-dose linearity). The pre-
sent EPA risk estimate for arsenic (5 x 10-5
lifetime risk of cancer per microgram per
liter ofarsenic in dfinking water), which is
based on this default assumption, implies
that a large part ofthe U.S. population is at
risk from present levels of arsenic in food
and dfinking water. The real risk, however,
critically depends on the shape of the
dose-response curve at low arsenic concen-
trations, which cannot be accurately deter-
mined from current epidemiologic data.
Fourhypothetical shapes ofadose-response
relationship are plotted in Figure 1 (these
curves are for illustration of concepts and
have not been fit to actual data on arsenic).
The risk of health effects or response is
shown on the vertical axis in Figure 1, and
the exposure as a daily ingested quantity or
dose is shown on the horizontal axis. The
default assumptions used by the EPA for
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Figure 1. Examples of dose-response relation-
ships. The threshold (T) is placed arbitrarily for
=lutain
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risk assessment lead to a dose-response
function that is linear at low exposures, as
illustrated bythe linearand linear-quadratic
curves. The probability ofthe health effect,
or risk, is about equal for both those curves
and proportional at the low end of the
exposurerange.
For the threshold curve, the risk is zero
below a threshold (T; arbitrarily placed on
the figure for illustration), butproportional
to dose above T. The nonlinear curve
shows a relationship in which some risk is
still present below T, but the slope, or risk
per unit exposure, decreases as the arsenic
concentration gets lower. In this case T
might be regarded as a practical threshold
for regulatory purposes. The sublinear
function illustrated by the nonlinear curve
rarely can be measured accurately enough
to determine the details of its shape or to
distinguish it from the threshold curve.
Application to arsenic. The epidemio-
logical data used for the EPA risk estimate
for arsenic came from a study in Taiwan
carried out in the 1960s (5,6), in which
arsenic concentrations in drinking water
were as much as 1,400 pg/l. Recent
research indicates there may have been
additional arsenic exposure through food
(48,49), so total arsenic intake approached
3,000 pg/day for some people in the areas
studied. A linear plus quadratic relation-
ship, illustrated in Figure 1, was used in the
EPA risk assessment (1). At levels ofa few
tens of micrograms per day relevant to
exposure from food and water in the
United States, the contribution ofthe qua-
dratic term is negligible.
The EPA estimates the annual cost of
compliance for drinking water treatment at
$24 million for the current MCL of50pg/l
and $2.1 billion for an MCL of2pg/I (50).
These figures do not indude start-up costs
and increased costs ofremediation. Ifthe
correct form ofthe dose-response relation-
ship is more akin to thegeneral shape ofthe
threshold ornonlinear curves than thelinear
orlinear-quadratic curves (Fig. 1), the MCL
for a fixedlifetime riskwould behigher and
less (possibly much less) costly to imple-
ment. Thatthe MCLshould becorrectly set
to protect public health, whatever the
appropriate MCL level may be, is not at
issue. Our concern on this point lies with
thedefaultassumption usedbythe EPAand
whetheritisappropriate forarsenic.
Some evidence suggests that the inci-
dence ofhealth effects may drop more than
proportionally to dose, making the correct
dose-response shape resemble the threshold
or nonlinear curves in Figure 1. The evi-
dence indudes metabolic studies in animals
(51), metabolic studies in human popula-
tions consuming drinking water with high
levels of arsenic (24, clinical studies of a
small number of human volunteers (54,
and genotoxicological studies ofthe arsenic
dose-response relationship (53). Some
recent analyses ofepidemiological data also
add to the uncertainty about the EPA's lin-
ear-at-low-dose assumption for arsenic
(54,55). Conflicting evidence has led to
contention, however, supporting the need
for further research. For example,
Hopenhayn-Rich et al. (56) conduded that
humanstudies do notsupportamethylation
threshold hypothesis. They analyzed data
from studies that measured urinary inorgan-
ic arsenic and the metabolites monomethy-
larsonic acid (MMA) and dimethylarsenic
acid (DMA) in different populations; they
found that, on average, 20-25% ofinorgan-
ic arsenic remains unmethylated regardless
ofthe exposure level. Further discussion of
these issues has appeared elsewhere (57-63).
Thesestudies maybe contrasted with equal-
ly recent studies from Mexico that do show
an impact ofarsenic dose on methylation,
particularlywhen considered in terms ofthe
DMA:MMAratio (64,65).
Ifa practical threshold (as illustrated by
the nonlinear curve in Fig. 1) for chronic
arsenic toxicitydoes exist, the public health
benefit from large expenditures to reduce
arsenic levels in water and soil will be
small, perhaps negligible. The magnitude
of these expenditures should be a strong
incentive to discoverwhether such a practi-
cal threshold is evident in the human data.
Because ofthe need to improve the quality
ofthe measurements ofboth arsenic expo-
sure levels and health effects in the existing
studies, such a determination will require
additional research.
Under a directive from Congress, the
National Academy of Sciences (NAS)
recendy reviewed the EPA's risk assessment
methodology for environmental carcino-
gens (47). The NAS supported the EPA's
use ofdefault assumptions (induding those
leading to a dose response that is linear at
low exposure, as in the linear and linear-
quadratic curves ofFig. 1) in the absence of
scientific information to the contrary. But,
the NAS urged that the defaults be replaced
when scientific information can provide a
better basis for assessing risk. Arsenic is an
example in which the scientific information
to support better risk assessment should be
obtainable, probably within 5-10 years and
at a cost that is very small compared to the
economic and public health stakes involved
(66,67). Prior to the NAS report, the EPA
ScienceAdvisory Board (SAB) recommend-
ed that the EPA replace its risk assessment
(1) with an approach that indudes informa-
tion on potentially nonlinear mechanisms
for detoxification of arsenic (6t. A subse-
quent 1992 SAB report proposed a detailed
research program to support improved risk
assessment (695, but this program was not
funded by the agency. Additional informa-
tion has appeared since the SAB reports
that reinforces the potential to improve
arsenic risk assessment (70).
Limitations of Information on
Arsenic
Biological mechanisms ofarsenic toxicity.
Inorganic arsenic is detoxified in the body
by enzymatic methylation. Methyl groups
are added sequentially to yield MMA and
DMA. The acute toxicity of the arsenic
species decreases about an order ofmagni-
tude with each additional methyl group (as
measured by the lethal dose, LD50). MMA
and DMA do not appear to cause DNA
mutations (i.e., they are not genotoxic)
except at high doses (71); thus, they are
believed to pose only minimal toxicological
risk. The evidence suggests that toxicity
results from the remaining inorganic
arsenic that is not methylated. For exam-
ple, a recent skin organotypic model for
arsenic demonstrated that arsenic, but not
MMA or DMA, caused cellular changes
with a cancerous appearance (72).
Several physiologically based pharmaco-
kinetic (PBPK) models are being developed
that relate intake of inorganic arsenic to
concentrations in tissue and, along with
metabolites MMA and DMA, in urine
(73-76). Recent observations from humans
exposed to relativelyhigh levels ofarsenic in
drinking water indicate a need to determine
ratios of inorganic arsenic, MMA, and
DMAas measured in urine, rather thanjust
the inorganic arsenic exposure, to evaluate
the saturation of metabolic detoxification
processes (22,77). It is important to recog-
nize that saturation of arsenic metabolism
does not mean that no detoxification of
arsenic occurs above a certain exposure
level, but that the relative effectiveness is
decreasedabove thatexposure level.
Toxicological studies, primarily in ani-
mals, demonstrate that nutritional deficien-
cies can result in impaired arsenic metabo-
lism (78). Thus, nutritional deficiencies may
contribute to the high incidence ofarsenic-
induced human health effects in India and
Taiwan (13-15). The 1989 SAB report (68)
noted thatsubgroups ofthepopulationwith
reducedmethylatingcapabilitymaybe more
prone to arsenic-induced cancer and other
health effects. The recent NAS report on
risk assessment (47) emphasizes the poten-
tial importance that genetic and nutritional
factors may have in causing risk levels to
vary among subgroups in the population.
Such variability may occur both between
and within countries.
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Existing epidemiological studies.
Although a large number of studies on
exposure or health effects related to arsenic
are either under way or completed, there
are only two major studies, both from
Taiwan, that link cancer prevalence or
mortality with exposure to arsenic at differ-
ent drinking water concentrations (which
we refer to as dose-response data) (5-9).
These studies demonstrate a dose-response
relationship for cancer at various sites and
arsenic concentrations in water, but the
data are not sufficiently precise for accurate
quantitative assessment of the magnitude
of cancer risk at different arsenic concen-
trations needed to set an MCL in the
United States because the studies report
exposures for groups ofpeople rather than
for individuals. (Such studies are referred
to as ecological studies.)
For example, theTseng study (5,6) used
in the 1988 EPA risk assessment collected
skin cancer data on individuals, but relied
on a previous study for exposure data on
wells tested for arsenic concentrations.
Participants were identified with a village
but not with the specific well within thevil-
lage used for drinking water. In some vil-
lages, only onewell was tested, and in those
with multiple tests, the outcomes covered a
wide range. The health effects were first
grouped by village, with the average well
concentration used as the exposure index
for thewholevillage. The health effects data
were then combined across villages with an
exposure index in the same interval, 0-300
pg/l, 300-600 jig/l, or >600 pg/l. The well
tests and average value for each village were
not reported in the published study (5). An
attempt to reconstruct the exposure data by
village in the Tseng study found that vil-
lages categorized in the 0-300 pg/l group
probably contained some wells with con-
centrations as high as 770 pg/l (79). Brown
et al. (80) provide a more general discussion
of uncertainty in arsenic risk assessment
thatincludes bladder cancer.
Other factors contribute further to
uncertainty in the exposure of individuals
in the Tseng study: arsenic concentrations
mayhave varied temporallywithin the same
well, as noted by Tseng (5); a person may
not have used the same water source
throughout a lifetime, particularly if a
change of residence occurred; and the
method used for the determination of
arsenic in the wells [attributed to Natelson
(5)] has poor accuracy and precision below
50 pg/l (81). In addition to drinking water,
food is an important contributor to total
intake of arsenic. Although data on the
arsenic content offoods in Taiwan are lim-
ited, it is clear that a large difference in
arsenic intake from food between the affect-
ed region ofTaiwan and the United States
would have a substantial impact on the esti-
mates oflifetime risk from arsenic in drink-
ingwater in the United States (48,49).
Research Needs
Epid&miology. New epidemiological studies
are needed to provide better information on
the shape ofthe dose-response relationship.
As noted previously, there are locations out-
side the United States where arsenic expo-
sure is current, or sufficiently recent, that
might be considered as potential study sites.
The central requirement is to match, in a
study population ofample size and range of
arsenic exposure histories, the presence or
absence ofadverse health effects in individ-
uals with knowledge of their long-term
exposure to arsenic. The range ofexposure
would ideally include drinking water con-
centrations below the current MCL of 50
pg/l to a few hundred micrograms per liter
and, if possible, to 1,000 pg/l. These
requirements might be met by an ongoing
study, as in Chile, but current and historical
information isverylimited.
To conduct a dose-response study, one
would need to evaluate the feasibility and
alternatives in candidate locations, such as
Bangladesh, West Bengal India, Thailand,
Taiwan, China, Inner Mongolia, Mexico,
Argentina, Chile, Finland, and Hungary.
Ideally, a study population would be sta-
tionary, with individuals having been
exposed to drinking water of known
arsenic concentrations for an extended and
known duration. Similarly, the contribu-
tion ofarsenic from food would need to be
known, and arsenic from all sources would
need to be speciated. In some countries
such as Taiwan, Hungary, and Mexico,
remediation of arsenic concentrations in
drinking water in endemic regions may
pose limitations on reconstruction ofexpo-
sure histories and the health endpoints that
could be evaluated in relation to that histo-
ry. For example, in some regions of
Mexico, drinking water concentrations of
arsenic were high until about 5 years ago,
when exposures were reduced. Such a loca-
tion may still be suitable to study an end-
point such as cancer, which has a long
latency period, but not to study biomarkers
ofcurrent exposure.
Some health endpoints may not have as
extended a latency period as cancer, or the
effects of exposure duration may be
unknown, e.g., cardiovascular disease or
adverse pregnancy outcome. Thus, the
health endpoints that may be studied in a
location, the existence of medical records
and arsenic exposure histories, and the type
ofepidemiological study (case-control, ret-
rospective cohort, prevalence, etc.) that
might be conducted are interrelated, making
it necessary to assess the potential for each
candidate study location separately. There
are, of course, additional issues related to
cooperation and participation by the host
country: existence of personnel, facilities,
and other resources and the cost and dura-
tion to complete a study. The AWWARF is
currently funding a project to study the
feasibility of conducting epidemiological
studies on arsenic, following research rec-
ommendations from a workshop held in
1995 (70).
Although previous epidemiological stud-
ies in the United States have not found evi-
dence ofexcess cancer associated with arsenic
exposure, further investigations are under
way that indude endpoints such as cardio-
vascular disease. However, the small number
ofpeople exposed to relatively high arsenic
levels in the United States and the limited
range ofexposure make the United States an
unlikely location for a dose-response study.
Additionally, the U.S. population is relatively
mobile, making it difficult to estimate
arsenic exposure over several decades of a
lifetime. By contrast, some populations with
high arsenic exposure outside the United
States are relativelystationary, thus providing
a better opportunity to assess lifetime expo-
sure. Also, exposed populations are much
larger than in the United States and exhibit a
much wider range ofexposure overwhich to
observe the shape ofthe dose-response rela-
tionship. Epidemiological study designs to
address potential high bladder cancer risks
from arsenic in drinking water are discussed
byVahterandMarafante (78).
Combining epidemiological with mech-
anistic studies in highly exposedpopula-
tions. Biomarkers are indicators in biologi-
cal media (e.g., urine, blood) that can be
used to measure either exposure or an effect
of exposure. A useful biomarker of recent
exposure to arsenic is inorganic arsenic and
its methylated metabolites in urine.
Quantification of inorganic arsenic and its
metabolites in urine can provide important
information on detoxification mechanisms
that influence the actual dose to tissues and
hence potential risk for cancers and other
chronic health effects. It may be possible to
use data from urine or other fluids or tissue
samples in epidemiological studies to corre-
late biological changes with the potential
for health effects.
Biomarkers ofeffect have only recently
been applied to arsenic research. An exam-
ple ofa biomarker ofeffect ofarsenic is the
presence ofmicronuclei in exfoliated blad-
der cells in urine (84, although this effect
is not specific to arsenic. Such biomarkers
can help us understand the disease process-
es and improve risk assessment.
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Biomarkers may be very important in
providing information on the mechanistic
relationship between arsenic exposure and
internal dose or between arsenic exposure
and cancer, or other adverse health effects.
For example, biomarkers mayhelp toverify
and estimate parameters for PBPK models
and to confirm whether certain types of
lesions or cell alterations are precursors to
cancer. Because there are no known bio-
markers ofeffect specific to arsenic, popu-
lation studies using such biomarkers must
consider the sensitivity ofsuch markers, as
well as address confounding exposures.
Exposure data for individuals over a
time scale of decades, combined with
mechanistic information and individual
health histories, would be the best basis for
determining the correct dose-response rela-
tionship. Data indicating the presence or
absence ofa practical threshold would have
very important implications for improving
the risk assessment for arsenic. Evidence
indicating that such a practical threshold
exists would indicate that the EPA's default
assumption oflow-dose linearity is incor-
rect for arsenic. Even stronger evidence
would be provided by confirmation of a
mode of action for which a practical
threshold is biologically plausible and a lin-
ear relationship is much less plausible. Such
a mode of action might involve saturation
ofa detoxification mechanism, interference
by arsenic species with cellular DNA repair
processes such those governed by the p53
oncogene (53,83), or other possible mecha-
nisms; these mechanisms maybe elucidated
by further research on highly exposed
human populations, supplemented by
mechanistic research in whole animals and
in vitrocellular studies.
Improved Risk Assessment Is
Needed to Manage the Risks
There is some inconsistency in federal reg-
ulation of arsenic by different organisms.
For example, there is no regulation of
arsenic in food, although food is the major
source ofarsenic for most Americans. The
Food and Drug Administration (FDA)
regards arsenic as a natural constituent in
food and is thus acceptable by default. On
the other hand, the EPA is legally required
to set allowable standards for arsenic in
drinking water and in water and soil at
Superfund sites.
Superfund guidance requires considera-
tion of soil screening levels (SSLs), which
are chemical concentrations in soil below
which there is no concern for human
health risk (41). An exceedance ofthe SSL
does not indicate the automatic need for
remedial action at a Superfund site, but
rather the need for further analysis. For
carcinogens, the EPA sets SSLs at the soil
concentration associated with a 10-6 risk.
In the case ofarsenic, the SSL is 0.4 mg/kg,
which is below the geometric mean arsenic
concentration of5 mg/kg for soils in many
areas of the United States (84). Thus,
arsenic in soil at background levels repre-
sents a natural source ofarsenic exposure.
The requirement of the EPA to revise
the MCL for arsenic in drinking water has
maintained interest in the 1988 EPA skin
cancer risk assessment; there has been dis-
cussion ofpossible reductions in the MCL
to 20 pg/l, 5 pg/l, or even 2 pg/l. As noted
previously, such reductions would incur
large costs to remove arsenic during water
treatment (50), costs that would be passed
on to the public. Expenditures for soil
remediation would also increase as arsenic
levels of 10-100 mg/kg and higher are
found near former copper mines and
smelters, manufacturing sites, and agricul-
tural areas where arsenical pesticides were
used in the nineteenth and early twentieth
centuries and at other locations where
arsenic compounds were used and then dis-
carded (85). The issuehere is not the dollar
value ofpublic health, but the large uncer-
tainty in how much the MCL may need to
be reduced to protect publichealth.
Recommendations ofthe
SEGH Arsenic Task Force for
Arsenic Research in Support
of Risk Assessment
* Research is needed to improve riskassess-
ment of arsenic without regard to the
regulatory timetable. Current disagree-
ments on issues related to arsenic toxici-
ty and exposure are largely due to
incomplete information needed for risk
assessment and perhaps to limitations of
current risk assessment methodology.
Scientific information relevant to health
effects assessment of arsenic has
advanced significantly during the past
decade, and research needs to be contin-
ued on its own time schedule. Arsenic
provides a good case study for improv-
ing cancer risk assessment methods to
include information about modes of
action and to investigate possible depar-
ture from the no-threshold default
assumption of low-dose linearity in
accordance with the 1994 recommenda-
tions from the National Academy of
Sciences (63). The NAS recommenda-
tions have been accepted in principle by
the EPA (86), and they have motivated
many of the changes in the EPA's pro-
posed revision of its cancer risk assess-
ment guidelines (87). Thus, we see fur-
ther research on arsenic as necessary to
improve risk assessment of arsenic in
drinking water and as an opportunity to
advance cancer riskassessment methods.
* More collaborative research should be
undertaken within the United States
between government agencies and other
interested parties and between the
United States and other countries with
similar research interests in arsenic.
Because so many countries have serious
arsenic-related health problems, there are
excellent opportunities for international
collaboration and cooperation. The EPA
draft arsenic research plan alludes to col-
laboration with Chile and India for
dose-response assessment of cancer at
internal sites, but to our knowledge, no
agreements are in place. Affected por-
tions ofU.S. industry have indicated a
willingness to co-fund research, includ-
ing research outside ofthe United States.
A large step in this direction is the coop-
eration ofthe EPA, AWWARF, and the
Association ofCaliforniaWaterAgencies
insolicitingapplications to support up to
$3 million of arsenic-related research.
We encourage funding groups to consult
the recommended list of research pro-
jects from the 1992 SAB report (69), the
recent EPA workshop on arsenic epi-
demiology (88), the report of the
AWWARF workshop on research needs
(71), and the draft EPA arsenic research
plan. Projects currently sponsored by
AWWARF may also contribute further
to the identification ofspecific research
needs.
* We urge expanded research and comple-
tion ofa new risk assessment by the year
2000 as an alternative to basing the
drinking water MCL on the EPA's 1988
riskassessment. Unlike the two preceding
recommendations, this one addresses the
short-term need to improve arsenic risk
assessment to set the MCL by the year
2000. The EPA draft arsenic research
plan is intended to meet this objective,
but it takes a very broad perspective with
limited setting ofpriorities. We believe
that the current EPA risk assessment on
skin cancer is inadequate. This is not the
fault ofthe EPA or ofthe dassic Tseng
study (5,6) on which the current risk
assessment is based; rather, it follows
from information learned subsequent to
the 1988 EPAriskassessmentaboutchar-
acteristics of the exposure data (80).
While these data provide strong evidence
that arsenic in drinking water causes skin
cancer and other adverse health effects,
theyare notwell suitedfordose-response
estimation needed to estimate riskofcan-
cer at low arsenic concentrations in water
as found in the United States. Moreover,
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the EPA's risk assessment is for skin can-
cer, although more recent data have
becomeavailablefromTaiwan; thesedata
show a relationship between arsenic and
cancer at internal sites, particularly the
bladder, which may pose a greater risk
than skin cancer (32). Our recommenda-
tion is to consider what useful research
can be completed by the year 2000 that
might improve the information base
needed to set an MCL. Initially this
should indude review ofrelevant research
that has appeared since the 1988 risk
assessment, in both toxicology and epi-
demiology, and becoming familiar with
ongoing and completed studies in other
countries with high-arsenic areas. In our
judgment, highest priority should be
given to epidemiological and mechanistic
research to clarify the shape of the
dose-response curve at exposures of
50-500 pg/day, or even lower, iffeasible,
for skin cancer and alternative endpoints,
such as bladder cancer, that might be
used to setthe MCL.
* The U.S. government should be more
consistent in assessing the risk from low
levels ofarsenic in water, soil, and food.
Total arsenic intake from all sources,
predominantly food and water in the
United States, should be taken into
account in setting standards to protect
public health, instead of one medium
(water) being addressed and another
(food) being dismissed. The FDA cur-
rently disregards arsenic in food as a
health risk because it occurs naturally in
the soil. But arsenic is no less toxic in
food than water because it is derived
from natural sources; arsenic in water is
similarly derived from natural sources
much ofthe time. Ifwe judge that 100,
40, or 10 pg/day from water is an unac-
ceptable risk to public health, we should
also investigate the extent to which this
level is exceeded due to exposure from
food. This will require the federal gov-
ernment to coordinate its activities and
objectives to protect public health from
harmful environmental substances.
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